306 related articles for article (PubMed ID: 37418320)
21. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
22. E3 ligase ligand optimization of Clinical PROTACs.
Jiang H; Xiong H; Gu SX; Wang M
Front Chem; 2023; 11():1098331. PubMed ID: 36733714
[TBL] [Abstract][Full Text] [Related]
23. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
[TBL] [Abstract][Full Text] [Related]
24. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.
Bricelj A; Steinebach C; Kuchta R; Gütschow M; Sosič I
Front Chem; 2021; 9():707317. PubMed ID: 34291038
[TBL] [Abstract][Full Text] [Related]
25. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
Dann GP; Liu H; Nowak RP; Jones LH
Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
[TBL] [Abstract][Full Text] [Related]
26. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
27. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
28. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
29. Cereblon: promise and challenges for combating human diseases.
Kim HK; Seol JE; Ahn SW; Jeon S; Park CS; Han J
Pflugers Arch; 2021 Nov; 473(11):1695-1711. PubMed ID: 34553266
[TBL] [Abstract][Full Text] [Related]
30. Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead.
Nowak RP; Ragosta L; Huerta F; Liu H; Ficarro SB; Cruite JT; Metivier RJ; Donovan KA; Marto JA; Fischer ES; Zerfas BL; Jones LH
RSC Chem Biol; 2023 Nov; 4(11):906-912. PubMed ID: 37920397
[TBL] [Abstract][Full Text] [Related]
31. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms of thalidomide and its derivatives.
Ito T; Handa H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
[TBL] [Abstract][Full Text] [Related]
33. A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions.
Guo L; Zhou Y; Nie X; Zhang Z; Zhang Z; Li C; Wang T; Tang W
Eur J Med Chem; 2022 Jun; 236():114317. PubMed ID: 35397401
[TBL] [Abstract][Full Text] [Related]
34. Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design.
Palomba T; Tassone G; Vacca C; Bartalucci M; Valeri A; Pozzi C; Cross S; Siragusa L; Desantis J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430693
[TBL] [Abstract][Full Text] [Related]
35. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
[TBL] [Abstract][Full Text] [Related]
36. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
37. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
38. Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation.
Hong SH; Divakaran A; Osa A; Huang OW; Wertz IE; Nomura DK
ACS Chem Biol; 2024 Feb; 19(2):442-450. PubMed ID: 38305738
[TBL] [Abstract][Full Text] [Related]
39. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
40. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]